Free Trial
→ Trump’s issues shocking Executive Order on U.S. Dollar (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:JUNS

Jupiter Neurosciences 12/23/2024 Earnings Results & Report

Jupiter Neurosciences logo
$2.85 +0.08 (+2.89%)
Closing price 10/9/2026 03:59 PM Eastern
Extended Trading
$2.87 +0.02 (+0.67%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Jupiter Neurosciences reported earnings on December 23, 2024. The company reported EPS of -$1.50.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Report Date
Time
After Market Closes

Jupiter Neurosciences EPS Results

Actual EPS
-$1.50
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
1 of last 6 quarters

Jupiter Neurosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Jupiter Neurosciences' next earnings date is estimated for Wednesday, December 2, 2026, based on past reporting schedules.

Conference Call Resources

Jupiter Neurosciences Earnings FAQ

Jupiter Neurosciences (NASDAQ:JUNS) reported earnings of -$1.50 per share for the quarter. The report was announced on Monday, December 23, 2024.

Jupiter Neurosciences' next earnings date is estimated for Wednesday, December 2, 2026. MarketBeat tracks confirmed and estimated earnings dates for Jupiter Neurosciences on the company's earnings history page.

Jupiter Neurosciences Earnings Headlines

Jupiter Neurosciences (NASDAQ:JUNS) Stock Jumps 18.2% - Time to Buy?
October 7 at 1:41 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31094279
Jupiter Neurosciences Starts Phase 2a Parkinson's Trial Of JOTROL
October 6, 2026  |  rttnews.comhttps://www.rttnews.com/3696943/jupiter-neurosciences-starts-phase-2a-parkinson-s-trial-of-jotrol.aspx
Analyst nicknamed “The Prophet” issues new warning for America
Whitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly 80% afterward. He also called the housing crisis and the collapse of Bear Stearns and Lehman Brothers before they happened. Now Tilson says the day after this year's midterm elections, America enters a period of economic change unlike anything seen in decades - and most investors are unprepared.tc pixel
October 10 at 1:00 AM  |  Stansberry Research (Ad)
Jupiter Neurosciences Announces First Patient Dosed in Phase 2a RESET Trial in Parkinson’s Disease and Exploration of Strategic Options to Maximize Shareholder Value
October 6, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/jupiter-neurosciences-announces-first-patient-dosed-in-phase-2a-reset-trial-in-parkinson-s-disease-and-exploration-of-strategic-options-to-maximize-shareholder-value-1036601560
Jupiter Neurosciences Announces First Patient Dosed in Phase 2a RESET Trial of JOTROL for Parkinson’s Disease and Reviews Strategic Alternatives
October 6, 2026  |  quiverquant.comQ
Jupiter Neurosciences Announces First Patient Dosed in Phase 2a RESET Trial in Parkinson's Disease and Exploration of Strategic Options to Maximize Shareholder Value
October 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/06/3375753/0/en/jupiter-neurosciences-announces-first-patient-dosed-in-phase-2a-reset-trial-in-parkinson-s-disease-and-exploration-of-strategic-options-to-maximize-shareholder-value.html
See More Jupiter Neurosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Jupiter Neurosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Jupiter Neurosciences and other key companies, straight to your email.

About Jupiter Neurosciences

Jupiter Neurosciences (NASDAQ:JUNS) is a clinical-stage biopharmaceutical company focused on developing therapies for neurological disorders associated with neuroinflammation. The company’s research centers on resveratrol, a naturally occurring compound that has been studied for potential anti-inflammatory and neuroprotective effects.

Its primary product candidate is JOTROL™, a proprietary oral formulation designed to improve the delivery and bioavailability of resveratrol. Jupiter Neurosciences is evaluating JOTROL for potential use in conditions including Alzheimer’s disease, Friedreich’s ataxia and other neurological disorders. The company’s programs remain in development, and its product candidates have not been approved for commercial use.

Jupiter Neurosciences is based in the United States and is conducting its work through preclinical and clinical development programs. Publicly available information about the company’s broader operations, geographic reach and leadership is limited.

View Jupiter Neurosciences Profile
Earnings Tools